文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Skp2 is a promising therapeutic target in breast cancer.

作者信息

Wang Zhiwei, Fukushima Hidefumi, Inuzuka Hiroyuki, Wan Lixin, Liu Pengda, Gao Daming, Sarkar Fazlul H, Wei Wenyi

机构信息

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

出版信息

Front Oncol. 2012 Jan 4;1(57). doi: 10.3389/fonc.2011.00057.


DOI:10.3389/fonc.2011.00057
PMID:22279619
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3263529/
Abstract

Breast cancer is the most common type of cancer among American women, and remains the second leading cause of cancer-related death for female in the United States. It has been known that several signaling pathways and various factors play critical roles in the development and progression of breast cancer, such as estrogen receptor, Notch, PTEN, human epidermal growth factor receptor 2, PI3K/Akt, BRCA1, and BRCA2. Emerging evidence has shown that the F-box protein S-phase kinase associated protein 2 (Skp2) also plays an important role in the pathogenesis of breast cancer. Therefore, in this brief review, we summarize the novel functions of Skp2 in the pathogenesis of breast cancer. Moreover, we provide further evidence regarding the state of our knowledge toward the development of novel Skp2 inhibitors especially natural "chemopreventive agents" as targeted approach for the prevention and/or treatment of breast cancer.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e70/3355927/8252e3a6db13/fonc-01-00057-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e70/3355927/bcc0649e1d4f/fonc-01-00057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e70/3355927/8252e3a6db13/fonc-01-00057-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e70/3355927/bcc0649e1d4f/fonc-01-00057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e70/3355927/8252e3a6db13/fonc-01-00057-g002.jpg

相似文献

[1]
Skp2 is a promising therapeutic target in breast cancer.

Front Oncol. 2012-1-4

[2]
Skp2: a novel potential therapeutic target for prostate cancer.

Biochim Biophys Acta. 2012-1

[3]
1,2,3,4,6-penta-O-galloyl-β-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein.

J Agric Food Chem. 2011-5-31

[4]
The expression and prognosis of Emi1 and Skp2 in breast carcinoma: associated with PI3K/Akt pathway and cell proliferation.

Med Oncol. 2013-10-25

[5]
USP18 promotes breast cancer growth by upregulating EGFR and activating the AKT/Skp2 pathway.

Int J Oncol. 2018-4-30

[6]
Role of Notch signaling pathway in pancreatic cancer.

Am J Cancer Res. 2017-2-1

[7]
FBXW2 suppresses breast tumorigenesis by targeting AKT-Moesin-SKP2 axis.

Cell Death Dis. 2023-9-22

[8]
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Breast Cancer Res. 2014-9-11

[9]
F-box protein FBXO41 suppresses breast cancer growth by inducing autophagic cell death through facilitating proteasomal degradation of oncogene SKP2.

Int J Biochem Cell Biol. 2022-6

[10]
Thioridazine reverses trastuzumab resistance in gastric cancer by inhibiting S-phase kinase associated protein 2-mediated aerobic glycolysis.

World J Gastroenterol. 2023-12-7

引用本文的文献

[1]
PHLPP1 depletion promotes tumorigenesis and stemness in triple-negative breast cancer cells through AKT signaling.

Med Oncol. 2025-2-20

[2]
CDK7/CDK9 mediates transcriptional activation to prime paraptosis in cancer cells.

Cell Biosci. 2024-6-10

[3]
PD-L1 intrinsically promotes the proliferation of breast cancer cells through the SKP2-p27/p21 axis.

Cancer Cell Int. 2024-5-9

[4]
Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans.

Cell Death Discov. 2024-5-9

[5]
AIbZIP/CREB3L4 Promotes Cell Proliferation via the SKP2-p27 Axis in Luminal Androgen Receptor Subtype Triple-Negative Breast Cancer.

Mol Cancer Res. 2024-4-2

[6]
Cecal microbiota and mammary gland microRNA signatures are related and modifiable by dietary flaxseed with implications for breast cancer risk.

Microbiol Spectr. 2024-1-11

[7]
Molecular targets and therapeutic strategies for triple-negative breast cancer.

Mol Biol Rep. 2023-12

[8]
FBXW2 suppresses breast tumorigenesis by targeting AKT-Moesin-SKP2 axis.

Cell Death Dis. 2023-9-22

[9]
Inhibitors Targeting the F-BOX Proteins.

Cell Biochem Biophys. 2023-12

[10]
Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.

Neuro Oncol. 2023-9-5

本文引用的文献

[1]
BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.

Science. 2011-10-28

[2]
Skp2: a novel potential therapeutic target for prostate cancer.

Biochim Biophys Acta. 2012-1

[3]
The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation.

Nat Rev Mol Cell Biol. 2011-8-23

[4]
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

CA Cancer J Clin. 2011-6-17

[5]
1,2,3,4,6-penta-O-galloyl-β-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein.

J Agric Food Chem. 2011-5-31

[6]
mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.

Expert Opin Ther Targets. 2011-4-8

[7]
Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.

Oncologist. 2011-3-15

[8]
Correlation of Skp2 overexpression to prognosis of patients with nasopharyngeal carcinoma from South China.

Chin J Cancer. 2011-3

[9]
Targeting the insulin-like growth factor network in cancer therapy.

Cancer Biol Ther. 2011-4-15

[10]
Gallic acid induces G2/M phase arrest of breast cancer cell MCF-7 through stabilization of p27(Kip1) attributed to disruption of p27(Kip1)/Skp2 complex.

J Agric Food Chem. 2011-2-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索